ERK1/2 Activation Drives Estrogen-Like Liver Injury by Psoralen Compounds

Study Background and Research Question

Cholestatic hepatic injury (CHI) is a significant clinical concern, characterized by impaired bile flow and accumulation of bile acids (BAs), which can progress to liver dysfunction. Notably, the incidence of estrogen-induced cholestasis (EC)—a subset of CHI—has risen with the increasing use of oral contraceptives and hormone replacement therapies. Epidemiological observations indicate a higher prevalence of CHI in women, implicating estrogen and estrogen-like compounds as key risk factors. Phytoestrogens, plant-derived molecules structurally similar to endogenous estrogens, have been recognized for their ability to bind estrogen receptors and modulate downstream signaling. However, the molecular mechanisms by which such compounds contribute to cholestasis remain incompletely defined. Psoraleae Fructus, the dried fruit of Psoralea corylifolia L., contains the major bioactive phytoestrogens psoralen (P) and isopsoralen (IP). Both have reported hepatotoxic potential, yet the specific pathways linking their estrogenic activity to cholestatic effects have not been systematically elucidated. The present study sought to determine whether P and IP induce EC via defined molecular mechanisms—specifically, the involvement of the RAS/RAF/MEK/ERK signaling cascade—and to evaluate whether ERK1/2 inhibition could mitigate the resulting liver injury (reference study).

Key Innovation from the Reference Study

The central innovation of this work is the demonstration that psoralen and isopsoralen mediate cholestatic hepatotoxicity through activation of the ERK1/2 signaling pathway. By employing both pharmacological inhibitors and genetic readouts, the study establishes ERK1/2 phosphorylation as a mechanistic nexus linking estrogenic signaling to impaired bile acid metabolism and transport. Notably, the application of a selective ERK1/2 inhibitor, GDC-0994, was shown to rescue the cholestatic phenotype in a zebrafish model, suggesting a translatable therapeutic avenue for mitigating phytoestrogen-induced liver injury.

Methods and Experimental Design Insights

The investigators utilized a larval zebrafish model—an established system for studying cholestatic liver diseases due to its optical transparency and conserved hepatobiliary architecture. Zebrafish larvae were exposed to 80 μM of psoralen or isopsoralen, with parallel groups treated with the aromatase antagonist exemestane (Exe) or the ERK1/2 inhibitor GDC-0994. The study assessed endpoints across several axes:

• Estrogenic activity: Expression of estrogen receptor 1 (esr1), aromatase (cyp19a1b), estradiol (E2) levels, and vitellogenin (VTG) were measured to confirm estrogen-like effects.
• Hepatotoxicity: Liver fluorescence area (marking hepatocellular injury) and bile flow inhibition rates were quantified.
• Gene expression: The mRNA levels of key genes governing bile acid synthesis (cyp7a1, cyp8b1), transport (abcb11b, slc10a1), and nuclear receptors (nr1h4—farnesoid X receptor, nr0b2a) were analyzed.
• Signal pathway activation: Phosphorylation status of ERK1/2 was evaluated by immunoblotting in zebrafish livers.
• Pharmacological rescue: Effects of ERK1/2 inhibition (GDC-0994) and aromatase antagonism (Exe) on cholestatic injury endpoints were systematically tested.

This multi-pronged approach enabled the dissection of estrogenic, genetic, and signaling contributions to cholestasis.

Core Findings and Why They Matter

The study’s principal findings are as follows:

• Estrogenic Activation: Both psoralen and isopsoralen increased the expression of esr1 and cyp19a1b, as well as E2 and VTG levels in zebrafish larvae. Exemestane, an aromatase antagonist, effectively blocked these estrogen-like effects.
• Cholestatic Liver Injury: Exposure to P or IP led to increased liver fluorescence (indicative of injury) and higher bile flow inhibition rates, confirming their hepatotoxicity in vivo.
• Disrupted Bile Acid Homeostasis: There was a significant decrease in the expression of bile acid synthesis genes (cyp7a1, cyp8b1), bile acid transporters (abcb11b, slc10a1), and nuclear receptors (nr1h4, nr0b2a), implicating broad impairment of BA metabolism and excretion.
• ERK1/2 Pathway Activation: Both compounds increased ERK1/2 phosphorylation—an event previously implicated in estrogen-induced cholestasis—suggesting that the MAP kinase pathway is a key mediator of the toxic effect.
• Pharmacological Rescue by ERK1/2 Inhibition: Treatment with GDC-0994, a potent and selective ERK1/2 inhibitor, significantly reduced cholestatic liver injury parameters, restoring gene expression profiles and hepatobiliary function. Exemestane also provided rescue, confirming the estrogenic origin of the effect (reference study).

These results collectively position ERK1/2 as a central effector in phytoestrogen-induced cholestasis and highlight the translational potential of ERK pathway inhibition for mitigating such hepatic toxicities.

Protocol Parameters

• Psoralen/isopsoralen exposure: 80 μM for zebrafish larvae, with phenotypic and molecular endpoints measured 72 hours post-treatment.
• ERK1/2 inhibitor (GDC-0994) administration: Co-treatment at concentrations validated for pathway inhibition (see product information for solubility and dosing guidance).
• Aromatase antagonist (exemestane): Applied as a positive control for estrogen pathway blockade.
• Bile acid analysis: Quantified via commercial kits; gene expression by qPCR; ERK phosphorylation by immunoblotting.

Comparison with Existing Internal Articles

Recent thought-leadership on ERK1/2 inhibition, such as the article "ERK1/2 Inhibition in Translational Liver Research: Beyond Oncology", contextualizes the mechanistic role of ERK1/2 inhibitors like GDC-0994 in hepatic applications. The reference study extends these discussions by providing direct experimental evidence that the RAS/RAF/MEK/ERK signaling cascade is not only relevant in oncogenic settings but also critically contributes to liver injury mechanisms elicited by estrogenic or phytoestrogenic compounds. Both sources converge on the concept that pathway-targeted inhibition offers a rational strategy for dissecting and modifying disease processes across domains—here, from cancer to toxicology and hepatology.

Limitations and Transferability

While the zebrafish model offers high-throughput and in vivo relevance, inter-species differences in hepatic metabolism and bile acid profiles must be considered before extrapolating to mammalian or human contexts. The concentrations of psoralen and isopsoralen used, though effective in the model, may not directly map to human exposure scenarios. Additionally, while GDC-0994 rescued cholestatic injury in zebrafish, its clinical efficacy and safety for this application remain untested in higher organisms. The study’s focus on early molecular events (e.g., gene expression and pathway activation) leaves open questions regarding long-term outcomes and the reversibility of established cholestasis.

Why this cross-domain matters, maturity, and limitations

The cross-domain bridge—from oncology to hepatology—is grounded in the mechanistic commonality of the MAP kinase pathway. As the reference study and internal articles both demonstrate, ERK1/2 inhibitors are invaluable not only for targeting tumor cell proliferation but also for dissecting and potentially mitigating complex liver injury mechanisms. However, translation to clinical hepatology is nascent; most evidence, including the present study, is preclinical and mechanistic. The maturity of this approach for therapeutic purposes is therefore limited by the lack of longitudinal and large-animal studies, as well as regulatory precedent.

Research Support Resources

Researchers interested in modeling ERK1/2 pathway inhibition in cholestatic liver injury or other applications can use GDC-0994 (SKU B5817), a highly selective ERK1/2 inhibitor validated in both oncology and hepatic protocols. Full product specifications, including solubility parameters and storage guidance, are available from APExBIO. For those designing workflows that require precise modulation of the RAS/RAF/MEK/ERK signaling cascade, GDC-0994 enables targeted inhibition of ERK phosphorylation and downstream signaling events, supporting advanced studies in liver biology and toxicology.